TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9626225

Group type: EXPERIMENTAL
Intervention: Topotecan 1.5 mg/m2 intravenously (i.v.) over 30 minutes daily for 5 days repeated every 21 days (arm A)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Topotecan 1.75 mg/m2 as a 24-hour infusion once a week for 4 weeks repeated every 6 weeks (arm B)
Number of subjects: 63
Study: 7949497

Group type: EXPERIMENTAL
Intervention: Nasal GH with 4% DDPC
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nasal GH with 8% DDPC
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nasal GH with 0% DDPC
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nasal GH with 16% DDPC
Number of subjects: 16
Study: 3278765

Group type: EXPERIMENTAL
Intervention: Conventional bolus dressing
Number of subjects: 40

Group type: COMPARATOR
Intervention: Quilting sutures and no dressing
Number of subjects: 40
Study: 31435692

Group type: EXPERIMENTAL
Intervention: rTMS combined with motor training (rTMS‐MT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Motor training (MT)
Number of subjects: 19
Study: 28654562

Group type: EXPERIMENTAL
Intervention: Ibuprofen treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 26899941

Group type: EXPERIMENTAL
Intervention: Sentinel Node Biopsy (SNB)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Observation (no axillary surgical staging)
Number of subjects: 176
Study: 25231109

Group type: EXPERIMENTAL
Intervention: Aerobic training (exercise group; n = 14)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (n = 19)
Number of subjects: 33
Study: 22817607

Group type: EXPERIMENTAL
Intervention: 12-month exercise intervention consisting of six individual guidance sessions with a physiotherapist and a home-based exercise program.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care arm (control group).
Number of subjects: 100
Study: 19638824

Group type: EXPERIMENTAL
Intervention: Cooper 12-Minute run/walk test (CT12)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Maximal oxygen consumption ((.)Vo2max)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Treadmill exercise time
Number of subjects: 45
Study: 17765608

Group type: EXPERIMENTAL
Intervention: Dual-chamber rate-modulated pacing (DDDR)
Number of subjects: 872

Group type: COMPARATOR
Intervention: Dual-chamber pacing (DDD)
Number of subjects: 872
Study: 14980942

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural anesthesia (CSE) with intrathecal hyperbaric 0.5% bupivacaine 5 mg and fentanyl 10 microg, followed by 0.9% saline 6.0 mL through the epidural catheter 5 min thereafter
Number of subjects: 62

Group type: COMPARATOR
Intervention: Single-shot spinal anesthesia with hyperbaric 0.5% bupivacaine 9 mg and fentanyl 10 microg
Number of subjects: 62
Study: 12127831

Group type: EXPERIMENTAL
Intervention: Appropriate care with hylan G‐F 20 (AC+H)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Appropriate care without hylan G‐F 20 (AC)
Number of subjects: 255
Study: 9619732

Group type: EXPERIMENTAL
Intervention: High-dose ara-C/daunorubicin (HDara-C/DNR) after idarubicin induction
Number of subjects: 27

Group type: COMPARATOR
Intervention: High-dose ara-C/daunorubicin (HDara-C/DNR) after daunorubicin induction
Number of subjects: 27
Study: 7633693

Group type: EXPERIMENTAL
Intervention: Nasal immunotherapy (LNIT) with Parietaria
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2675377

Group type: EXPERIMENTAL
Intervention: Felodipine (5 mg x 2/day for two weeks, then 10 mg x 2/day for two months)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Atenolol (100 mg/day for two months)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 113

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 113
Study: 359017

Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temazepam (10 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temazepam (20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temazepam (30 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxazepam (15 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxazepam (30 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nordiazepam (5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nordiazepam (10 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxazepam (45 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg) morning ingestion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temazepam (20 mg) morning ingestion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxazepam (30 mg) morning ingestion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nordiazepam (10 mg) morning ingestion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg) choice response time test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temazepam (20 mg) choice response time test
Number of subjects: 0
Study: 30339211

Group type: EXPERIMENTAL
Intervention: First-generation e-cigs (white)
Number of subjects: 3364

Group type: EXPERIMENTAL
Intervention: Second-generation e-cigs
Number of subjects: 3364

Group type: EXPERIMENTAL
Intervention: Third-generation e-cigs
Number of subjects: 3364
Study: 31552710

Group type: EXPERIMENTAL
Intervention: LCD + INT (n=13; 12 supervised 60-min INT bouts of 3 min at 90% and 50% HRpeak)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: LCD + INT
Number of subjects: 25

Group type: COMPARATOR
Intervention: LCD (n=12)
Number of subjects: 25

Group type: COMPARATOR
Intervention: LCD
Number of subjects: 25
Study: 28193455

Group type: EXPERIMENTAL
Intervention: Endotracheal tube with subglottic secretion drainage (ETT‐SD) and cuff pressure monitorization
Number of subjects: 133

Group type: COMPARATOR
Intervention: Standard endotracheal tube (control)
Number of subjects: 133
Study: 25833972

Group type: EXPERIMENTAL
Intervention: WinFood (WF)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: WinFood-Lite (WF-L)
Number of subjects: 419

Group type: COMPARATOR
Intervention: CSB+
Number of subjects: 419

Group type: COMPARATOR
Intervention: CSB++
Number of subjects: 419
Study: 23332309

Group type: COMPARATOR
Intervention: Externally unsupported thin wall knitted polyester (P-non-EXS)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Externally supported thin wall knitted polyester (P-EXS)
Number of subjects: 265
Study: 21844392

Group type: EXPERIMENTAL
Intervention: DNA prime
Number of subjects: 0

Group type: COMPARATOR
Intervention: rAd5 prime
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DNA vaccination
Number of subjects: 0
Study: 19288533

Group type: EXPERIMENTAL
Intervention: Castor oil capsule 0.9 mL, thrice daily for 4 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Diclofenac sodium capsule 50 mg, thrice daily for 4 weeks
Number of subjects: 100
Study: 16881913

Group type: EXPERIMENTAL
Intervention: Individualized, pre- and post-natal lactation consultant (LC) intervention
Number of subjects: 382

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 382
Study: 14748914

Group type: EXPERIMENTAL
Intervention: Blood pressure reduction
Number of subjects: 1000000

Group type: EXPERIMENTAL
Intervention: Angiotensin‐converting enzyme inhibition
Number of subjects: 1000000

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor antagonism
Number of subjects: 1000000

Group type: EXPERIMENTAL
Intervention: Calcium channel blockade
Number of subjects: 1000000

Group type: EXPERIMENTAL
Intervention: Cholesterol reduction
Number of subjects: 1000000

Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 1000000

Group type: EXPERIMENTAL
Intervention: Erythropoietin therapy
Number of subjects: 1000000

Group type: EXPERIMENTAL
Intervention: Dietary protein restriction
Number of subjects: 1000000

Group type: EXPERIMENTAL
Intervention: Intensive glycaemic control
Number of subjects: 1000000

Group type: EXPERIMENTAL
Intervention: Early intensive multidisciplinary patient education within a renal unit
Number of subjects: 1000000

Group type: EXPERIMENTAL
Intervention: Specific interventions for atherosclerotic renal artery stenosis, diabetic nephropathy, lupus nephritis, and certain forms of primary glomerulonephritis
Number of subjects: 1000000
Study: 11395029

Group type: EXPERIMENTAL
Intervention: Fortified fat spread (25 g/day providing 2.5 g of plant sterols)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo spread
Number of subjects: 62
Study: 9232297

Group type: EXPERIMENTAL
Intervention: PCEA using meperidine with background infusion (group Pi)
Number of subjects: 40

Group type: COMPARATOR
Intervention: PCEA using meperidine without background infusion (group Po)
Number of subjects: 40
Study: 8125422

Group type: EXPERIMENTAL
Intervention: Captopril (ACE inhibitor), started after the first day but within 72 hours of onset of chest pain
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 3021006

Group type: EXPERIMENTAL
Intervention: Low carbohydrate/low fiber dietary advice
Number of subjects: 135

Group type: COMPARATOR
Intervention: Higher carbohydrate/higher fiber regimen
Number of subjects: 135
Study: 29736497

Group type: COMPARATOR
Intervention: Chlorhexidine mouthrinse (0.2%; CHX; positive control)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ASF toothpaste
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: HTP toothpaste
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: STP toothpaste
Number of subjects: 24
Study: 27206612

Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus clomiphene citrate
Number of subjects: 116

Group type: COMPARATOR
Intervention: Clomiphene citrate
Number of subjects: 116
Study: 25392618

Group type: EXPERIMENTAL
Intervention: da Vinci single-console
Number of subjects: 40

Group type: COMPARATOR
Intervention: da Vinci dual-console
Number of subjects: 40
Study: 22768459

Group type: EXPERIMENTAL
Intervention: Aminophylline (5 mg/kg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (5% dextrose water for injection, 5 cc/kg)
Number of subjects: 22
Study: 16510384

Group type: EXPERIMENTAL
Intervention: Topical Symphytum product Traumaplant (10% active ingredient)
Number of subjects: 215

Group type: COMPARATOR
Intervention: 1% reference product (2.5 g of fresh comfrey herb in 100 g of cream)
Number of subjects: 215
Study: 12168688

Group type: EXPERIMENTAL
Intervention: Gluten and casein-free diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (standard diet)
Number of subjects: 20
Study: 10540994

Group type: EXPERIMENTAL
Intervention: Anatomic reconstruction using a periosteal flap
Number of subjects: 10

Group type: COMPARATOR
Intervention: Evans tenodesis
Number of subjects: 10
Study: 8848206

Group type: EXPERIMENTAL
Intervention: Bromocriptine (up to 60 mg/d)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 2081142

Group type: EXPERIMENTAL
Intervention: Verapamil SR 120 mg (V120 SR) given twice daily (bid)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Verapamil SR 240 mg (V240 SR) given once daily (od)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 35414

Group type: EXPERIMENTAL
Intervention: Clonidine (2 X 0.025 mg/24 hours - 0.075 mg/24 hours, increased if necessary at intervals of two weeks)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 37
Study: 29499583

Group type: EXPERIMENTAL
Intervention: Amniotic Fluid Index (AFI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single Deepest Vertical Pocket (SDP)
Number of subjects: 0
Study: 27449226

Group type: EXPERIMENTAL
Intervention: mHealth reinforcement
Number of subjects: 84

Group type: COMPARATOR
Intervention: mHealth monitoring
Number of subjects: 84
Study: 26635090

Group type: EXPERIMENTAL
Intervention: Probiotic (prOVag®) with metronidazole
Number of subjects: 578

Group type: COMPARATOR
Intervention: Placebo with metronidazole
Number of subjects: 578
Study: 24075772

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (0.05 mg/d)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Etanercept (25 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 21440672

Group type: EXPERIMENTAL
Intervention: 10 mg bisacodyl once daily for 4 weeks
Number of subjects: 368

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 368
Study: 19146605

Group type: EXPERIMENTAL
Intervention: Topical application of Arctium lappa fruit extract-containing formulation for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical application of Arctium lappa fruit extract-containing formulation for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: In vitro studies with pure Arctiin
Number of subjects: 0
Study: 16567815

Group type: EXPERIMENTAL
Intervention: Dietary counseling (biannually)
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Control group (no dietary counseling)
Number of subjects: 1062
Study: 14531561

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil-releasing microspheres
Number of subjects: 0
Study: 10750765

Group type: EXPERIMENTAL
Intervention: High dose aprotinin
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 80

Group type: COMPARATOR
Intervention: Aprotinin
Number of subjects: 80
Study: 8935813

Group type: EXPERIMENTAL
Intervention: Sertindole 20 mg/day
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Sertindole (various doses)
Number of subjects: 205
Study: 1411095

Group type: EXPERIMENTAL
Intervention: Budesonide (400 micrograms daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 3159639

Group type: EXPERIMENTAL
Intervention: HBV vaccine alone (Group I)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: HBV vaccine + HBIG at birth (Group II)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: HBV vaccine + HBIG at birth and again at one month (Group III)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (Group IV)
Number of subjects: 114
Study: 30518444

Group type: EXPERIMENTAL
Intervention: Ambulatory level III device with end tidal carbon dioxide (etCO2)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Level I polysomnography (PSG)
Number of subjects: 28
Study: 26903575

Group type: EXPERIMENTAL
Intervention: mFOLFOX6 plus SIRT
Number of subjects: 530

Group type: COMPARATOR
Intervention: mFOLFOX6 (control)
Number of subjects: 530
Study: 24799541

Group type: EXPERIMENTAL
Intervention: Palivizumab
Number of subjects: 532

Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 532
Study: 22734376

Group type: EXPERIMENTAL
Intervention: Acupuncture-rehabilitation group (routine rehabilitation therapy combined with electroacupuncture therapy)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Acupuncture-rehabilitation group
Number of subjects: 70

Group type: COMPARATOR
Intervention: Rehabilitation group
Number of subjects: 70
Study: 20348364

Group type: EXPERIMENTAL
Intervention: Stage of Change measure
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Decisional Balance measure
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Self-efficacy measure
Number of subjects: 293
Study: 18458247

Group type: EXPERIMENTAL
Intervention: Five annual screening examinations
Number of subjects: 1520
Study: 16380690

Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acids (PUFAs)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 22
Study: 12058428

Group type: EXPERIMENTAL
Intervention: Amrinone (5 mcg.kg‐1.min‐1) administered after coronary artery anastomosis (A 1 group: 11 cases)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Amrinone (5 mcg.kg‐1.min‐1) administered after induction of anesthesia (A 2 group: 13 cases)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (non-amrinone group: 17 cases)
Number of subjects: 41
Study: 10326147

Group type: EXPERIMENTAL
Intervention: Captopril 150 mg/day
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 504
Study: 8603632

Group type: EXPERIMENTAL
Intervention: Felbamate (FBM) at doses of 1,200, 2,400, 3,000, or 3,600 mg/day (n = 2-4 per group)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Felbamate (FBM)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 1936112

Group type: EXPERIMENTAL
Intervention: 54Fe-labelled iron preparation (150 mg Fe2+ daily)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Commercially available iron preparation (160 mg Fe2+ daily)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both preparations
Number of subjects: 18
Study: 7011299

Group type: EXPERIMENTAL
Intervention: Scopolamine hydrobromide 0.3 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Scopolamine hydrobromide 0.3 mg + ephedrine hydrochloride 25 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31720795

Group type: EXPERIMENTAL
Intervention: Laparoscopic distal gastrectomy (LDG)
Number of subjects: 380
Study: 30540490

Group type: EXPERIMENTAL
Intervention: Face-to-Face (FtF) communication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) communication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Online Text-Based (OTB) communication
Number of subjects: 0
Study: 28514613

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 25612789

Group type: EXPERIMENTAL
Intervention: Early discharge strategy (EDS: <72 h, followed by outpatient lifestyle interventions)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional discharge strategy (CDS)
Number of subjects: 100
Study: 23434915

Group type: EXPERIMENTAL
Intervention: Different examples of different textures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different examples of the same texture
Number of subjects: 0
Study: 21208446

Group type: EXPERIMENTAL
Intervention: High Glycemic Index (HGI) meals
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Low Glycemic Index (LGI) meals
Number of subjects: 15
Study: 19565729

Group type: EXPERIMENTAL
Intervention: Acupuncture at points of The Liver and Gallbladder Meridians
Number of subjects: 253

Group type: COMPARATOR
Intervention: Western medicine group (Flunarizine tablets)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Acupuncture group
Number of subjects: 253
Study: 17419283

Group type: COMPARATOR
Intervention: 250 mg clarithromycin (C250 group)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: 250 mg clarithromycin and 500 mg vitamin C (V-C250 group)
Number of subjects: 171

Group type: COMPARATOR
Intervention: 500 mg clarithromycin (C500 group)
Number of subjects: 171

Group type: COMPARATOR
Intervention: All groups (C250, V-C250, C500)
Number of subjects: 171
Study: 15671923

Group type: EXPERIMENTAL
Intervention: Self-declared diabetic patients
Number of subjects: 67
Study: 11157010

Group type: COMPARATOR
Intervention: Doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² every 3 weeks (arm A)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Mitoxantrone 23 mg/m² plus cyclophosphamide 600 mg/m² with filgrastim 5 µg/kg/d from days 2 to 15 every 3 weeks (arm B)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Mitoxantrone 23 mg/m² plus cyclophosphamide with filgrastim (arm B)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² (arm A)
Number of subjects: 150
Study: 9830317

Group type: EXPERIMENTAL
Intervention: Hemodialysis patients
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Transplanted patients
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control group (general population)
Number of subjects: 181
Study: 8005064

Group type: EXPERIMENTAL
Intervention: Combined chemo- and radiotherapy without preceding operation
Number of subjects: 23

Group type: COMPARATOR
Intervention: Surgical resection followed by chemo- and/or radiotherapy
Number of subjects: 23
Study: 2920548

Group type: EXPERIMENTAL
Intervention: Benztropine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Glycopyrrolate (active placebo)
Number of subjects: 12
Study: 31424391

Group type: EXPERIMENTAL
Intervention: Self-reported SMCs measured with the Prospective and Retrospective Memory Questionnaire (PRMQ)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Self-reported retrospective memory problems
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Self-reported prospective memory problems
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Informant-reported memory problems
Number of subjects: 303
Study: 29326333

Group type: EXPERIMENTAL
Intervention: Disease management intervention (self‐management programme, home telemonitoring, care coordination, medical management)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Usual management practices
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Disease management intervention
Number of subjects: 319
Study: 26508701

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogens (0.45 mg/day) with progesterone (200 mg/day for 12 days each month)
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Transdermal 17β‐estradiol (50 μg/day) with progesterone (200 mg/day for 12 days each month)
Number of subjects: 606

Group type: COMPARATOR
Intervention: Placebo pills and patch
Number of subjects: 606
Study: 25386086

Group type: EXPERIMENTAL
Intervention: Splenic artery banding (n=28)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (n=15)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Temporary blockade of the splenic artery
Number of subjects: 43
Study: 22564540

Group type: EXPERIMENTAL
Intervention: Multiparametric MRI examination followed by a second TRUS-guided prostate biopsy
Number of subjects: 180

Group type: COMPARATOR
Intervention: Second random TRUS-guided prostate biopsy
Number of subjects: 180
Study: 20150839

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day
Number of subjects: 56

Group type: COMPARATOR
Intervention: No statin treatment
Number of subjects: 56
Study: 18577956

Group type: EXPERIMENTAL
Intervention: Memantine 20 mg/d
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 23
Study: 15626966

Group type: EXPERIMENTAL
Intervention: Neck exercise program with activation of deep neck muscles and dynamic strengthening for 6 weeks
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Neck exercise program
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group (infrared irradiation and neck care advice)
Number of subjects: 145